Gadolinium and Multiple Sclerosis: Vessels, Barriers of the Brain, and Glymphatics

References

1. 1.↵
   2. Rocca MA,
   3. Absinta M,
   4. Filippi M

   . The role of advanced magnetic resonance imaging techniques in primary progressive MS. J Neurol 2012;259:611–21 doi:10.1007/s00415-011-6195-6 pmid:21814822

   CrossRefPubMed
2. 2.↵
   2. Río J,
   3. Castilló J,
   4. Rovira A, et al

   . Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009;15:848–53 doi:10.1177/1352458509104591 pmid:19542263

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Bou Fakhredin R,
   3. Saade C,
   4. Kerek R, et al

   . Imaging in multiple sclerosis: a new spin on lesions. J Med Imaging Radiat Oncol 2016;60:577–86 doi:10.1111/1754-9485.12498 pmid:27464473

   CrossRefPubMed
4. 4.↵
   2. Wu GF,
   3. Alvarez E

   . The immunopathophysiology of multiple sclerosis. Neurol Clin 2011;29:257–78 doi:10.1016/j.ncl.2010.12.009 pmid:21439440

   CrossRefPubMed
5. 5.↵
   2. Love S,
   3. Louis DN,
   4. Ellison DW

   . Greenfield's Neuropathology. 8th ed. London: Hodder Arnold; 2008
6. 6.↵
   2. Keegan M,
   3. König F,
   4. McClelland R, et al

   . Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005;366:579–82 doi:10.1016/S0140-6736(05)67102-4 pmid:16099294

   CrossRefPubMedWeb of Science
7. 7.↵
   2. Henderson AP,
   3. Barnett MH,
   4. Parratt JD, et al

   . Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009;66:739–53 doi:10.1002/ana.21800 pmid:20035511

   CrossRefPubMedWeb of Science
8. 8.↵
   2. de Rosbo NK,
   3. Kaye JF,
   4. Eisenstein M, et al

   . The myelin-associated oligodendrocytic basic protein region MOBP15–36 encompasses the immunodominant major encephalitogenic epitope(s) for SJL/J mice and predicted epitope(s) for multiple sclerosis-associated HLA-DRB1*1501. J Immunol 2004;173:1426–35 doi:10.4049/jimmunol.173.2.1426 pmid:15240739

   Abstract/FREE Full Text
9. 9.↵
   2. Greer JM,
   3. Csurhes PA,
   4. Cameron KD, et al

   . Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 1997;120(Pt 8):1447–60 doi:10.1093/brain/120.8.1447 pmid:9278634

   CrossRefPubMedWeb of Science
10. 10.↵
    2. Pette M,
    3. Fujita K,
    4. Wilkinson D, et al

    . Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci U S A 1990;87:7968–72 doi:10.1073/pnas.87.20.7968 pmid:1700423

    Abstract/FREE Full Text
11. 11.↵
    2. Valli A,
    3. Sette A,
    4. Kappos L, et al

    . Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest 1993;91:616–28 doi:10.1172/JCI116242 pmid:7679413

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Zhang J,
    3. Markovic-Plese S,
    4. Lacet B, et al

    . Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994;179:973–84 doi:10.1084/jem.179.3.973 pmid:7509366

    Abstract/FREE Full Text
13. 13.↵
    2. Brucklacher-Waldert V,
    3. Stuerner K,
    4. Kolster M, et al

    . Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009;132(Pt 12):3329–41 doi:10.1093/brain/awp289 pmid:19933767

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Durelli L,
    3. Conti L,
    4. Clerico M, et al

    . T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009;65:499–509 doi:10.1002/ana.21652 pmid:19475668

    CrossRefPubMedWeb of Science
15. 15.↵
    2. Tzartos JS,
    3. Friese MA,
    4. Craner MJ, et al

    . Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172:146–55 doi:10.2353/ajpath.2008.070690 pmid:18156204

    CrossRefPubMedWeb of Science
16. 16.↵
    2. Kebir H,
    3. Kreymborg K,
    4. Ifergan I, et al

    . Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007;13:1173–75 doi:10.1038/nm1651 pmid:17828272

    CrossRefPubMed
17. 17.↵
    2. Perry VH,
    3. Nicoll JA,
    4. Holmes C

    . Microglia in neurodegenerative disease. Nat Rev Neurol 2010;6:193–201

    CrossRefPubMedWeb of Science
18. 18.↵
    2. Bodini B,
    3. Cercignani M,
    4. Toosy A, et al

    . A novel approach with “skeletonised MTR” measures tract-specific microstructural changes in early primary-progressive MS. Hum Brain Mapp 2014;35:723–33 doi:10.1002/hbm.22196 pmid:23616276

    CrossRefPubMed
19. 19.↵
    2. Broom KA,
    3. Anthony DC,
    4. Blamire AM, et al

    . MRI reveals that early changes in cerebral blood volume precede blood-brain barrier breakdown and overt pathology in MS-like lesions in rat brain. J Cereb Blood Flow Metab 2005;25:204–16 doi:10.1038/sj.jcbfm.9600020 pmid:15678123

    CrossRefPubMedWeb of Science
20. 20.↵
    2. Lassmann H

    . Relapsing-remitting and primary progressive MS have the same cause(s): the neuropathologist's view, 1. Mult Scler 2013;19:266–67 doi:10.1177/1352458512474091 pmid:23426169

    CrossRefPubMed
21. 21.↵
    2. Karthikeyan K,
    3. Mahat MY,
    4. Chandrasekaran S, et al

    . Bioanalytical method development, validation and quantification of dorsomorphin in rat plasma by LC-MS/MS. Biomed Chromatogr 2013;27:1018–26 pmid:23526253

    PubMed
22. 22.↵
    2. Campbell JL,
    3. Le Blanc JC

    . Peptide and protein drug analysis by MS: challenges and opportunities for the discovery environment. Bioanalysis 2011;3:645–57 doi:10.4155/bio.11.31 pmid:21417733

    CrossRefPubMed
23. 23.↵
    2. Fernández M,
    3. Montalban X,
    4. Comabella M

    . Orchestrating innate immune responses in multiple sclerosis: molecular players. J Neuroimmunol 2010;225:5–12 doi:10.1016/j.jneuroim.2010.05.014 pmid:20537409

    CrossRefPubMed
24. 24.↵
    2. Sloane JA,
    3. Batt C,
    4. Ma Y, et al

    . Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc Natl Acad Sci U S A 2010;107:11555–60 doi:10.1073/pnas.1006496107 pmid:20534434

    Abstract/FREE Full Text
25. 25.↵
    2. Mathey EK,
    3. Derfuss T,
    4. Storch MK, et al

    . Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007;204:2363–72 doi:10.1084/jem.20071053 pmid:17846150

    Abstract/FREE Full Text
26. 26.↵
    2. Mahad DJ,
    3. Ziabreva I,
    4. Campbell G, et al

    . Mitochondrial changes within axons in multiple sclerosis. Brain 2009;132(Pt 5):1161–74 doi:10.1093/brain/awp046 pmid:19293237

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Scott P

    . New breakthroughs involving oligodendrocytes and stems cells, and their impact on multiple sclerosis. Microreviews in Cell and Molecular Biology 2012;1. https://undergradsciencejournals.okstate.edu/index.php/MRCMB/article/view/1987. Accessed February 5, 2018.
28. 28.↵
    2. Mallik S,
    3. Samson RS,
    4. Wheeler-Kingshott CA, et al

    . Imaging outcomes for trials of remyelination in multiple sclerosis. J Neurol Neurosurg Psychiatry 2014;85:1396–404 doi:10.1136/jnnp-2014-307650 pmid:24769473

    Abstract/FREE Full Text
29. 29.↵
    2. Swanton JK,
    3. Fernando K,
    4. Dalton CM, et al

    . Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2006;77:830–33 doi:10.1136/jnnp.2005.073247 pmid:16043456

    Abstract/FREE Full Text
30. 30.↵
    2. Geurts JJ,
    3. Calabrese M,
    4. Fisher E, et al

    . Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012;11:1082–92 doi:10.1016/S1474-4422(12)70230-2 pmid:23153407

    CrossRefPubMedWeb of Science
31. 31.↵
    2. Lorentzen J,
    3. Grey MJ,
    4. Crone C, et al

    . Distinguishing active from passive components of ankle plantar flexor stiffness in stroke, spinal cord injury and multiple sclerosis. Clin Neurophysiol 2010;121:1939–51 doi:10.1016/j.clinph.2010.02.167 pmid:20457538

    CrossRefPubMedWeb of Science
32. 32.↵
    2. Obermeier B,
    3. Daneman R,
    4. Ransohoff RM

    . Development, maintenance and disruption of the blood-brain barrier. Nat Med 2013;19:1584–96 doi:10.1038/nm.3407 pmid:24309662

    CrossRefPubMed
33. 33.↵
    2. Goriely A,
    3. Geers MG,
    4. Holzapfel GA, et al

    . Mechanics of the brain: perspectives, challenges, and opportunities. Biomech Model Mechanobiol 2015;14:931–65 doi:10.1007/s10237-015-0662-4 pmid:25716305

    CrossRefPubMed
34. 34.↵
    2. Yasuda T,
    3. Fukumura K,
    4. Sato Y, et al

    . Effects of detraining after blood flow-restricted low-intensity training on muscle size and strength in older adults. Aging Clin Exp Res 2014;26:561–64 doi:10.1007/s40520-014-0208-0 pmid:24639094

    CrossRefPubMed
35. 35.↵
    2. Bammer R,
    3. Augustin M,
    4. Strasser-Fuchs S, et al

    . Magnetic resonance diffusion tensor imaging for characterizing diffuse and focal white matter abnormalities in multiple sclerosis. Magn Reson Med 2000;44:583–91 doi:10.1002/1522-2594(200010)44:4<583::AID-MRM12>3.0.CO%3B2-O pmid:11025514

    CrossRefPubMedWeb of Science
36. 36.↵
    2. Enzinger C,
    3. Barkhof F,
    4. Ciccarelli O, et al

    ; MAGNIMS study group. Nonconventional MRI and microstructural cerebral changes in multiple sclerosis. Nat Rev Neurol 2015;11:676–86 doi:10.1038/nrneurol.2015.194 pmid:26526531

    CrossRefPubMed
37. 37.↵
    2. Lucchinetti CF,
    3. Popescu BF,
    4. Bunyan RF, et al

    . Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011;365:2188–97 doi:10.1056/NEJMoa1100648 pmid:22150037

    CrossRefPubMedWeb of Science
38. 38.↵
    2. Iliff JJ,
    3. Goldman SA,
    4. Nedergaard M

    . Implications of the discovery of brain lymphatic pathways. Lancet Neurol 2015;14:977–79 doi:10.1016/S1474-4422(15)00221-5 pmid:26376966

    CrossRefPubMed
39. 39.↵
    2. Chaitanya GV,
    3. Omura S,
    4. Sato F, et al

    . Inflammation induces neuro-lymphatic protein expression in multiple sclerosis brain neurovasculature. J Neuroinflammation 2013;10:895 doi:10.1186/1742-2094-10-125 pmid:24124909

    CrossRefPubMed
40. 40.↵
    2. Eide PK,
    3. Ringstad G

    . MRI with intrathecal MRI gadolinium contrast medium administration: a possible method to assess glymphatic function in human brain. Acta Radiol Open 2015;4:2058460115609635 pmid:26634147

    CrossRefPubMed
41. 41.↵
    2. Jessen NA,
    3. Munk AS,
    4. Lundgaard I, et al

    . The glymphatic system: a beginner's guide. Neurochem Res 2015;40:2583–99 doi:10.1007/s11064-015-1581-6 pmid:25947369

    CrossRefPubMed
42. 42.↵
    2. Bakker EN,
    3. Bacskai BJ,
    4. Arbel-Ornath M, et al

    . Lymphatic clearance of the brain: perivascular, paravascular and significance for neurodegenerative diseases. Cell Mol Neurobiol 2016;36:181–94 doi:10.1007/s10571-015-0273-8 pmid:26993512

    CrossRefPubMed
43. 43.↵
    2. Ratner V,
    3. Zhu L,
    4. Kolesov I, et al

    . Optimal-mass-transfer-based estimation of glymphatic transport in living brain. Proc SPIE Int Soc Opt Eng 2015;9413 doi:10.1117/12.2076289 pmid:26877579

    CrossRefPubMed
44. 44.↵
    2. Bilston LE,
    3. Stoodley MA,
    4. Fletcher DF

    . The influence of the relative timing of arterial and subarachnoid space pulse waves on spinal perivascular cerebrospinal fluid flow as a possible factor in syrinx development. J Neurosurg 2010;112:808–13 doi:10.3171/2009.5.JNS08945 pmid:19522574

    CrossRefPubMedWeb of Science
45. 45.↵
    2. Kanda T,
    3. Nakai Y,
    4. Oba H, et al

    . Gadolinium deposition in the brain. Magn Reson Imaging 2016;34:1346–50 doi:10.1016/j.mri.2016.08.024 pmid:27613998

    CrossRefPubMed
46. 46.↵
    2. Naganawa S,
    3. Nakane T,
    4. Kawai H, et al

    . Gd-based contrast enhancement of the perivascular spaces in the basal ganglia. Magn Reson Med Sci 2017;16:61–65 doi:10.2463/mrms.mp.2016-0039 pmid:27430361

    CrossRefPubMed
47. 47.↵
    2. Ramalho M,
    3. Ramalho J,
    4. Burke LM, et al

    . Gadolinium retention and toxicity: an update. Adv Chronic Kidney Dis 2017;24:138–46 doi:10.1053/j.ackd.2017.03.004 pmid:28501075

    CrossRefPubMed
48. 48.↵
    2. Gasperini C,
    3. Paolillo A,
    4. Rovaris M, et al

    . A comparison of the sensitivity of MRI after double-and triple-dose Gd-DTPA for detecting enhancing lesions in multiple sclerosis. Magn Reson Imaging 2000;18:761–63

    CrossRefPubMed
49. 49.↵
    2. McDonald RJ,
    3. McDonald JS,
    4. Kallmes DF, et al

    . Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities. Radiology 2017;285:546–54 doi:10.1148/radiol.2017161595 pmid:28653860

    CrossRefPubMed
50. 50.↵
    2. Smirniotopoulos JG,
    3. Murphy FM,
    4. Rushing EJ, et al

    . Patterns of contrast enhancement in the brain and meninges. Radiographics 2007;27:525–51 doi:10.1148/rg.272065155 pmid:17374867

    CrossRefPubMedWeb of Science
51. 51.↵
    2. Gaitán MI,
    3. Shea CD,
    4. Evangelou IE, et al

    . Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol 2011;70:22–29 doi:10.1002/ana.22472 pmid:21710622

    CrossRefPubMed
52. 52.↵
    2. Tintore M,
    3. Rovira A

    . MRI criteria distinguishing seropositive NMO spectrum disorder from MS. Neurology 2013;80:1336 doi:10.1212/WNL.0b013e3182887998 pmid:23486884

    CrossRefPubMed
53. 53.↵
    2. Davis PC,
    3. Bravo O,
    4. Gehrke M, et al

    . Development and validation of an LC-MS/MS method for the determination of quetiapine and four related metabolites in human plasma. J Pharm Biomed Anal 2010;51:1113–19 doi:10.1016/j.jpba.2009.11.018 pmid:20022726

    CrossRefPubMedWeb of Science
54. 54.↵
    2. Yin H,
    3. Davis T,
    4. Porter NA

    . Simultaneous analysis of multiple lipid oxidation products in vivo by liquid chromatographic-mass spectrometry (LC-MS). Methods Mol Biol 2010;610:375–86 doi:10.1007/978-1-60327-029-8_22 pmid:20013190

    CrossRefPubMed
55. 55.↵
    2. Fischer M,
    3. Kunkel A,
    4. Bublak P, et al

    . How reliable is the classification of cognitive impairment across different criteria in early and late stages of multiple sclerosis? J Neurol Sci 2014;343:91–99 doi:10.1016/j.jns.2014.05.042 pmid:24950898

    CrossRefPubMed
56. 56.↵
    2. Medrano Martorell S,
    3. Cuadrado Blázquez M,
    4. García Figueredo D, et al

    . Hyperintense punctiform images in the white matter: a diagnostic approach [in Spanish]. Radiología 2012;54:321–35 doi:10.1016/j.rx.2011.09.015 pmid:22284561

    CrossRefPubMed
57. 57.↵
    2. Ge Y,
    3. Law M,
    4. Johnson G, et al

    . Dynamic susceptibility contrast perfusion MR imaging of multiple sclerosis lesions: characterizing hemodynamic impairment and inflammatory activity. AJNR Am J Neuroradiol 2005;26:1539–47 pmid:15956527

    Abstract/FREE Full Text
58. 58.↵
    2. González-Quintanilla V,
    3. Oterino A,
    4. Toriello M, et al

    . Cluster-tic syndrome as the initial manifestation of multiple sclerosis. J Headache Pain 2012;13:425–29 doi:10.1007/s10194-012-0449-2 pmid:22543446

    CrossRefPubMed
59. 59.↵
    2. Takao H,
    3. Abe O,
    4. Yamasue H, et al

    . Gray and white matter asymmetries in healthy individuals aged 21–29 years: a voxel-based morphometry and diffusion tensor imaging study. Hum Brain Mapp 2011;32:1762–73 doi:10.1002/hbm.21145 pmid:20886579

    CrossRefPubMedWeb of Science
60. 60.↵
    2. Kilsdonk ID,
    3. Barkhof F,
    4. Wattjes MP

    . 2010 revisions to McDonald criteria for diagnosis of multiple sclerosis: impact of 3-Tesla magnetic resonance imaging. Ann Neurol 2011;70:182–83 doi:10.1002/ana.22490 pmid:21710623

    CrossRefPubMed
61. 61.↵
    2. Seewann A,
    3. Vrenken H,
    4. Kooi EJ, et al

    . Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosis. Mult Scler 2011;17:1202–10 doi:10.1177/1352458511406575 pmid:21561955

    CrossRefPubMed
62. 62.↵
    2. Grabner G,
    3. Dal-Bianco A,
    4. Schernthaner M, et al

    . Analysis of multiple sclerosis lesions using a fusion of 3.0 T FLAIR and 7.0 T SWI phase: FLAIR SWI. J Magn Reson Imaging 2011;33:543–49 doi:10.1002/jmri.22452 pmid:21563237

    CrossRefPubMed
63. 63.↵
    2. de Graaf WL,
    3. Kilsdonk ID,
    4. Lopez-Soriano A, et al

    . Clinical application of multi-contrast 7-T MR imaging in multiple sclerosis: increased lesion detection compared to 3 T confined to grey matter. Eur Radiol 2013;23:528–40 doi:10.1007/s00330-012-2619-7 pmid:22898935

    CrossRefPubMed
64. 64.↵
    2. Harrison AM,
    3. das Nair R,
    4. Moss-Morris R

    . Operationalising cognitive fatigability in multiple sclerosis: a Gordian knot that can be cut? Mult Scler 2017;23:1682–96 doi:10.1177/1352458516681862 pmid:27903936

    CrossRefPubMed
65. 65.↵
    2. Patejdl R,
    3. Penner IK,
    4. Noack TK, et al

    . Multiple sclerosis and fatigue: a review on the contribution of inflammation and immune-mediated neurodegeneration. Autoimmun Rev 2016;15:210–20 doi:10.1016/j.autrev.2015.11.005 pmid:26589194

    CrossRefPubMed
66. 66.↵
    2. Absinta M,
    3. Cortese IC,
    4. Vuolo L, et al

    . Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. Neurology 2017;88:1439–44 doi:10.1212/WNL.0000000000003820 pmid:28283598

    Abstract/FREE Full Text
67. 67.↵
    2. Kwee RM,
    3. Kwee TC

    . Virchow-Robin spaces at MR imaging. Radiographics 2007;27:1071–86 doi:10.1148/rg.274065722 pmid:17620468

    CrossRefPubMedWeb of Science
68. 68.↵
    2. Pollock H,
    3. Hutchings M,
    4. Weller RO, et al

    . Perivascular spaces in the basal ganglia of the human brain: their relationship to lacunes. J Anat 1997;191(Pt 3):337–46 doi:10.1046/j.1469-7580.1997.19130337.x pmid:9418990

    CrossRefPubMed